Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
We believe further capital return initiatives are likely to be announced alongside AMP’s FY25 result. industry feedback also points to the potential continuation of strong North flows while S&I should be on track for positive flows in FY26. Add this to strong cost control and ongoing stabilisation in
underlying bank earnings
extended its current on-market share buyback, allowing up to an additional $750 million of capital to be returned over a further 12-month period ending March 5, 2027, to take the total program to up to $1.5 billion.
Mesoblast rallied 8.5 per cent as it reported $US35.1 million in gross revenue from Ryoncil sales in the December quarter, up 60 per cent on the prior period.
Mesoblast made its first commercial sales of Ryoncil in March last year after the US Food and Drug Administration approved the therapy to treat children for complications that could occur during bone marrow transplants. The company on Friday reported $US35.1 million ($52.4 million) in sales of Ryoncil in the three months to December 31. This was a 60 per cent jump from the September quarter.
Level 17 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453
